Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
High inter-patient variability and high spatial heterogeneity are features of colorectal cancer (CRC). This may influence the molecular characterization of tumor tissue, now mandatory for patients with metastatic CRC who are candidates for treatment with an anti-EGFR mAb, as false-negative results can occur, leading to non optimal therapy. Moreover, temporal molecular heterogeneity during treatment is known to influence the response to therapy and prognosis. We present a literature overview of advances made in characterizing molecular heterogeneity in CRC, underlining that the analysis of liquid biopsy could represent an efficient non-invasive tool to overcome the problem. We believe that understanding CRC heterogeneity is fundamental for a more accurate diagnosis, for selecting the best targets to ensure prolonged antitumor response, and for monitoring minimal residual disease and the onset of resistance to therapy, all essential components of successful personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Heterogeneity, or more specifically, the diverse cell populations within the diseased tissue, is the leading cause of treatment failure for many complex diseases, such as cancers1, Alzheimer’s disease2, stroke3, and coronavirus disease 2019 (COVID-19)4, etc., as well as a major obstacle to successful precision medicine5–7.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“The majority of sporadic CRCs (almost 85%) arise from adenomas according to the model proposed by Fearon and Vogelstein in 1990 [16].”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 2×
“Finally, distinct mutations can also co-exist within the cells of a single metastatic lesion [7].”
BackgroundGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“to classify CRCs into four subtypes [12,22,29].”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 2×
“In Europe the overall survival (OS) rate for mCRC is estimated at 12%, with a median OS of 30 months [3].”
BackgroundClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · cited 1×
“The lack of accurate standard methods to assess ITH is currently limiting our ability to explore its clinical implications [39].”
BackgroundIntra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000 · cited 1×
“In fact, a higher spatial and temporal variability of tumor microenvironment components, such as stromal, inflammatory, and microbial cells, may translate into a higher phenotypic heterogeneity of tumor cells [30].”
BackgroundEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Figure 2a summarizes the possible scenario in this patient setting, where KRAS mutations represent the principal mechanism of acquired resistance and can be detected non-invasively in blood months before the appearance of radiographic progression [105].”
BackgroundFitzmaurice, C., & Global Burden of Disease Cancer Collaboration (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,646
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2706 · Cited by 1,518
Epidemiology and Management of Liver Metastases From Colorectal Cancer
Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., & Bouvier, A.-M. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000217629.94941.cf · Cited by 1,394 · cited 1×
“Around 20% of patients present with synchronous liver metastases [56], while another 40% develop metachronous liver metastases after resection of the primary tumor [57].”
BackgroundA Big Bang model of human colorectal tumor growth
Sottoriva, A., Kang, H., Ma, Z., Graham, T. A., Salomon, M. P., Zhao, J., Marjoram, P., Siegmund, K., Press, M. F., Shibata, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3214 · Cited by 1,015 · cited 6×
“In Sottoriva’s study, more than 300 individual glands from 15 CRCs were profiled by massive genomic characterization, revealing that ITH derives from early passenger alterations rather than from clonal selection.”
BackgroundResultInfluentialAdam, R., Pascal, G., Castaing, D., Azoulay, D., Delvart, V., Paule, B., Levi, F., & Bismuth, H. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000145964.08365.01 · Cited by 1,001 · cited 1×
“Chemotherapy (CT) may be recommended before surgery if metastatic disease is confined to the liver or if there is a limited metastatic disease in the lung [5].”
BackgroundCancer heterogeneity: implications for targeted therapeutics
Fisher, R., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 978 · cited 1×
“Thus, spatial heterogeneity is at the basis of resistance to treatment, especially when selective pressure has been exerted, for example, by drugs in late-stage cancers [34].”
BackgroundGenomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
Grady, W. M., & Carethers, J. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.076 · Cited by 960 · cited 1×
“In this era of precision medicine, it must be taken into account that CRC is characterized by high inter-patient heterogeneity and high intra-tumor heterogeneity (ITH), given the remarkable genomic instability (microsatellite and genomic instability) and field cancerization of the disease [6,7].”
BackgroundPatterns of metastasis in colon and rectal cancer
Riihimäki, M., Hemminki, A., Sundquist, J., & Hemminki, K. (2016) · Scientific Reports · doi:10.1038/srep29765 · Cited by 947 · cited 1×
“The second most common metastatic site is the lung [58,59], followed by the peritoneum (around 10% of patients) [60,61].”
BackgroundColorectal cancer liver metastases – a population-based study on incidence, management and survival
Engstrand, J., Nilsson, H., Strömberg, C., Jonas, E., & Freedman, J. (2018) · BMC Cancer · doi:10.1186/s12885-017-3925-x · Cited by 896
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858 · cited 2×
“CRC originating in the left colon and rectum has a higher incidence of liver and lung metastases than that of right-sided cancer, which shows a higher rate of peritoneal metastases and other-site metastases [55].”
BackgroundPan-cancer analysis of the extent and consequences of intratumor heterogeneity
Andor, N., Graham, T. A., Jansen, M., Xia, L. C., Aktipis, C. A., Petritsch, C., Ji, H. P., & Maley, C. C. (2016) · Nature Medicine · doi:10.1038/nm.3984 · Cited by 768 · cited 1×
“Furthermore, some studies have suggested that heterogeneity, measured by the existence of multiple subclonal alterations within the same tumor, may be associated with poor outcomes in many cancers [37].”
BackgroundVariable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M. K., Ng, K., Ma, J., Wienholds, E., Dunant, C., et al. (2013) · Science · doi:10.1126/science.1227670 · Cited by 744 · cited 1×
“in CRC, there may also be functional heterogeneity between tumor cells with a uniform genetic lineage, with cells differently capable of growing and responding to chemotherapy [32].”
BackgroundTejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 1×
“The different origins of left- and right-sided tumors lead to different gene expression and mutation profiles, ultimately influencing prognosis [20].”
BackgroundClinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678 · cited 1×
“[101] 95 Intplex qPCR KRAS BRAF 39%/38% 6%/6% 92%/98% 100%/100% 96% 100% Spindler et al.”
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673 · cited 1×
“using highly sensitive picodroplet digital PCR, suggested that in patients with mCRC showing KRAS-mutated subclones, ≤1% benefitted from anti-EGFR therapies, while others did not [51].”
MethodDistal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Soneson, C., Budinska, E., Popovici, V., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Ogino, S., Chan, A. T., Fuchs, C. S., & Giovannucci, E. (2011) · Gut · doi:10.1136/gut.2010.217182 · Cited by 522 · cited 1×
“This has become a new research field known as molecular pathological epidemiology (MPE), whose aim is to provide novel insights into interactions among the environment, tumor, and host to better understand how endogenous and exogenous factors modify tumor phenotypes [10,11].”
BackgroundTaly, V., Pekin, D., Benhaim, L., Kotsopoulos, S. K., Le Corre, D., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 492
Origins of lymphatic and distant metastases in human colorectal cancer
Naxerova, K., Reiter, J. G., Brachtel, E., Lennerz, J. K., van de Wetering, M., Rowan, A., Cai, T., Clevers, H., Swanton, C., Nowak, M. A., et al. (2017) · Science · doi:10.1126/science.aai8515 · Cited by 484 · cited 3×
“Otherwise, liver metastases may arise in later stages of disease from more stable clones and therefore appear to have more mutations, but also to be more homogeneous [82].”
BackgroundGuidelines for resection of colorectal cancer liver metastases
Garden, O. J. (2006) · Gut · doi:10.1136/gut.2006.098053 · Cited by 417 · cited 1×
“Around 20% of patients present with synchronous liver metastases [56], while another 40% develop metachronous liver metastases after resection of the primary tumor [57].”
BackgroundMitry, E., Guiu, B., Cosconea, S., Jooste, V., Faivre, J., & Bouvier, A.-M. (2010) · Gut · doi:10.1136/gut.2010.211557 · Cited by 377 · cited 1×
“The second most common metastatic site is the lung [58,59], followed by the peritoneum (around 10% of patients) [60,61].”
BackgroundBrannon, A., Vakiani, E., Sylvester, B. E., Scott, S. N., McDermott, G., Shah, R. H., Kania, K., Viale, A., Oschwald, D. M., Vacic, V., et al. (2014) · Genome Biology · doi:10.1186/preaccept-1207406452128377 · Cited by 372 · cited 1×
“hypothesized that prior chemotherapy treatment results in a decrease in apparent tumor heterogeneity [69].”
BackgroundLemmens, V. E., Klaver, Y. L., Verwaal, V. J., Rutten, H. J., Coebergh, J. W. W., & de Hingh, I. H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25596 · Cited by 352 · cited 1×
“The second most common metastatic site is the lung [58,59], followed by the peritoneum (around 10% of patients) [60,61].”
BackgroundVidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344 · cited 2×
“The authors found that peritoneal and lung metastases, and mucinous histology, were associated with low RAS cfDNA detection, whereas the number of metastases was not, suggesting that intrinsic biological characteristics of the tumor rather than tumor burden may impact cfDNA release [99].”
BackgroundExploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 295 · cited 1×
“observed multiple tumor subclones characterized by resistance-related alterations emerging during therapy that originate from different metastases throughout the body [109].”
BackgroundKnijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N., D'Angelica, M., Viale, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2994 · Cited by 282
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H.-J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 277 · cited 1×
“Finally, the microbial richness and composition that is believed to play an important part in the formation of CRC vary on the basis of the primary tumor location [25].”
BackgroundMisale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263 · cited 1×
“Remarkably, not only KRAS alterations, but also NRAS and BRAF mutations, as well as amplification of ERBB2 and MET, are detected in patients who respond to EGFR blockade and then relapse, highlighting that although the mechanisms of resistance are genetically heterogeneous, they converge on key signaling pathways [106…”
BackgroundMorelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 254 · cited 4×
“analysis of plasma collected at progression in 60 patients refractory to anti-EGFR mAbs and KRAS wt revealed the presence of KRAS mutation in 44% of cases [107].”
BackgroundInfluentialOgino, S., Nowak, J. A., Hamada, T., Milner, D. A., & Nishihara, R. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012818 · Cited by 252 · cited 1×
“This has become a new research field known as molecular pathological epidemiology (MPE), whose aim is to provide novel insights into interactions among the environment, tumor, and host to better understand how endogenous and exogenous factors modify tumor phenotypes [10,11].”
BackgroundSpindler, K.-L. G., Pallisgaard, N., Vogelius, I., & Jakobsen, A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0564 · Cited by 251 · cited 2×
“were among the first to analyze the concordance of KRAS mutation between tissue and cfDNA, obtaining a sensitivity of 78% and absolute specificity, as none of the patients without mutations in primary tumor tissue showed positive plasma samples [95].”
BackgroundGasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A. M., Mauermann, O., Izbicki, J. R., Pantel, K., & Riethdorf, S. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.188557 · Cited by 227 · cited 1×
“Of note, even KRAS status in CTCs from the same patient proved to be heterogeneous [90].”
BackgroundFabbri, F., Carloni, S., Zoli, W., Ulivi, P., Gallerani, G., Fici, P., Chiadini, E., Passardi, A., Frassineti, G. L., Ragazzini, A., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.015 · Cited by 223 · cited 1×
“reported a concordance of only 50% in their case series of 40 CRC patients [86].”
BackgroundSelf-citationEuropean cancer mortality predictions for the year 2018 with focus on colorectal cancer
Malvezzi, M., Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., La Vecchia, C., & Negri, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy033 · Cited by 211 · cited 1×
“2/100,000 for women has been predicted for 2018 [4].”
BackgroundGastrointestinal cancer and brain metastasis: A rare and ominous sign
Go, P. H., Klaassen, Z., Meadows, M. C., & Chamberlain, R. S. (2011) · Cancer · doi:10.1002/cncr.25940 · Cited by 199 · cited 1×
“Ovarian metastases occur in 5%–10% of all women with mCRC [62], while brain metastases are relatively rare, with a reported incidence of 1%–2% [63].”
BackgroundMutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., Lauricella, C., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7286 · Cited by 192
Grasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J. M., Paéz, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 187 · cited 2×
“[100] 146 Beaming RAS 39%/46% 85%/91% 90% Schmiegel et al.”
BackgroundMolecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Wang, W., Kandimalla, R., Huang, H., Zhu, L., Li, Y., Gao, F., Goel, A., & Wang, X. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.002 · Cited by 187 · cited 1×
“It has also been shown that multi-omic data integration at genetic, epigenetic, transcriptomic, and proteomic levels is needed to further understand the heterogeneity of primary and metastatic lesions [40].”
BackgroundPietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182 · cited 1×
“In a case series of 20 RAS-BRAF wt patients showing progression after anti-EGFR mAbs treatment, NGS analysis revealed that RAS mutations and HER2/MET amplifications were the most frequently detected resistance mechanisms in both tissue and plasma samples, the authors demonstrating the involvement of both intralesion a…”
BackgroundBachet, J. B., Bouché, O., Taieb, J., Dubreuil, O., Garcia, M. L., Meurisse, A., Normand, C., Gornet, J. M., Artru, P., Louafi, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy061 · Cited by 178 · cited 1×
“These results confirm the high concordance between primary tissue and liver metastases, suggesting that liquid biopsy could be contemplated for patients in this subgroup for whom no tumor tissue is available [104].”
ResultConsensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models
Linnekamp, J. F., Hooff, S. R. V., Prasetyanti, P. R., Kandimalla, R., Buikhuisen, J. Y., Fessler, E., Ramesh, P., Lee, K. A. S. T., Bochove, G. G. W., de Jong, J. H., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0011-5 · Cited by 177 · cited 2×
“The need to better characterize the molecular features of CRC heterogeneity has also been acknowledged given the varied response of patients with similar phenotypes to therapy [15].”
BackgroundEvolution of intratumoral genetic heterogeneity during colorectal cancer progression
Losi, L., Baisse, B., Bouzourene, H., & Benhattar, J. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi044 · Cited by 174 · cited 1×
“However, this was not true for 5q and 18q allelic losses, suggesting that a high level of CIN is not compensated by clonal selection [54].”
BackgroundJia, S., Zhang, R., Li, Z., & Li, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17184 · Cited by 171 · cited 2×
“Given its concentration and abundant content, exosomes could help to increase the sensitivity of liquid biopsy, despite the presence of some methodological limitations [92].”
BackgroundIntegrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine
Ogino, S., Nowak, J. A., Hamada, T., Phipps, A. I., Peters, U., Milner Jr, D. A., Giovannucci, E. L., Nishihara, R., Giannakis, M., Garrett, W. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315537 · Cited by 169 · cited 2×
“In addition, different immune cell distribution and action, influenced by local tumor cells, stroma, and microenvironmental factors, such as microbiota, contributes to spatial heterogeneity in CRC [9].”
BackgroundVermaat, J. S., Nijman, I. J., Koudijs, M. J., Gerritse, F. L., Scherer, S. J., Mokry, M., Roessingh, W. M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1965 · Cited by 153 · cited 1×
“This indicates that genetic analysis of metastases may have greater predictive power when patients are selected for specific treatment modalities, thus allowing for further refinement of treatment algorithms [75].”
BackgroundSchmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152 · cited 1×
“[102] 98 Beaming RAS 51%/53% 90%/94% 91.”
Kim, M.-J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J.-O., Bang, S.-M., Park, K. U., Kim, D.-W., Kang, S.-B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 140 · cited 1×
“, peritoneum) would seem to be affected by PIK3CA mutations rather than by KRAS status [83,84].”
BackgroundIntratumor genetic heterogeneity in advanced human colorectal adenocarcinoma
Baisse, B., Bouzourene, H., Saraga, E. P., Bosman, F. T., & Benhattar, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1343 · Cited by 137 · cited 1×
“demonstrated that 67% of the advanced CRCs analyzed had ITH when gene alterations and loss of heterozygosity (LOH) were examined in 15–20 areas within the tumor, indicating the importance of tumor sampling [44].”
BackgroundLiquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
Hench, I. B., Hench, J., & Tolnay, M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00009 · Cited by 128 · cited 1×
“discussed the advantages and limitations of CTC and ctDNA evaluation in breast, lung, and CRC, envisioning a potential role of liquid biopsy for second-line diagnosis and tumor surveillance, even though its analytical and clinical validity has yet to be definitively demonstrated [85].”
BackgroundAre KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 126 · cited 1×
“Interestingly, some authors have hypothesized that even mCRC patients with KRAS mutations may be a heterogeneous population, reporting that only patients with KRAS G13D mutation rather than KRAS G12R mutation show a survival benefit from treatment with targeted therapy combined with chemotherapy [19].”
BackgroundNormanno, N., Abate, R. E., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx417 · Cited by 119 · cited 2×
“3%, with 10 cases of RAS mutated in tissue and RAS wt in plasma, and a further 10 cases of RAS mutated in plasma and RAS wt in tissue [103].”
BackgroundComparative Genomic Analysis of Primary and Synchronous Metastatic Colorectal Cancers
Lee, S. Y., Haq, F., Kim, D., Jun, C., Jo, H.-J., Ahn, S.-M., & Lee, W.-S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090459 · Cited by 117 · cited 1×
“reported that about half of the liver lesions analyzed from mCRC showed genetic heterogeneity with respect to their corresponding primary CRC, indicating the need to evaluate metastatic lesions separately to optimize therapy rather than using primary tumor data [74].”
BackgroundThierry, A. R., Messaoudi, S. E., Mollévi, C., Raoul, J., Guimbaud, R., Pezet, D., Artru, P., Assénat, E., Borg, C., Mathonnet, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx330 · Cited by 117 · cited 1×
“[97] 34 97 Intplex qPCR RAS BRAF 12%/9% 14%/7% 67%/94% 57%/89% 92% 87% Grasselli et al.”
Cremolini, C., Antoniotti, C., Lonardi, S., Bergamo, F., Cortesi, E., Tomasello, G., Moretto, R., Ronzoni, M., Racca, P., Loupakis, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy140 · Cited by 112
Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer
Bramsen, J. B., Rasmussen, M. H., Ongen, H., Mattesen, T. B., Ørntoft, M.-B. W., Árnadóttir, S. S., Sandoval, J., Laguna, T., Vang, S., Øster, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.045 · Cited by 110 · cited 2×
“Moreover, there is evidence that exogenous factors such as lifestyle, diet, nutrition, environment, and microbiome contribute to pathogenesis, also influencing non neoplastic cells, including immune cells, and leading to further heterogeneity [8,9].”
BackgroundMao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107 · cited 3×
“reported that lymph node metastases showed a lower concordance rate of KRAS mutation status [14].”
BackgroundTreatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution
Venkatesan, S., Swanton, C., Taylor, B. S., & Costello, J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026617 · Cited by 106
Immune checkpoints and immunotherapy for colorectal cancer
Singh, P. P., Sharma, P. K., Krishnan, G., & Lockhart, A. C. (2015) · Gastroenterology report · doi:10.1093/gastro/gov053 · Cited by 101 · cited 1×
“MSI-H tumors make up a minority of CRCs, with a favorable prognosis in early-stage disease and a lower frequency in more advanced stages [18].”
BackgroundMoretto, R., Cremolini, C., Rossini, D., Pietrantonio, F., Battaglin, F., Mennitto, A., Bergamo, F., Loupakis, F., Marmorino, F., Berenato, R., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0084 · Cited by 101
Jass, J. R., & Smith, M. J. (1992) · Pathology · doi:10.3109/00313029209068874 · Cited by 100
Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 97
Denis, J. A., Patroni, A., Guillerm, E., Pépin, D., Benali-Furet, N., Wechsler, J., Manceau, G., Bernard, M., Coulet, F., Larsen, A. K., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.05.009 · Cited by 96 · cited 2×
“analyzed primary tumor tissue and CTCs in 11 patients, observing a concordance of around 64% in KRAS mutational status [87], while other studies obtained a concordance of 71–77% [88,89].”
ResultPrimary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Østerlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt253 · Cited by 92
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
Consensus molecular subtype classification of colorectal adenomas
Komor, M. A., Bosch, L. J., Bounova, G., Bolijn, A. S., Delis‐van Diemen, P. M., Rausch, C., Hoogstrate, Y., Stubbs, A. P., de Jong, M., Jenster, G., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5129 · Cited by 86 · cited 1×
“to classify CRCs into four subtypes [12,22,29].”
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82 · cited 1×
“found that all the metastatic lesions from 25 patients with multiple liver metastases and 11 patients with multiple lung metastases showed identical KRAS mutations, highlighting the importance of KRAS status in the primary tumor [79].”
BackgroundBeije, N., Helmijr, J., Weerts, M. J. A., Beaufort, C. M., Wiggin, M., Marziali, A., Verhoef, C. K., Sleijfer, S., Jansen, M. P. H. M., & Martens, J. W. M. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.10.001 · Cited by 80 · cited 1×
“analyzed a panel of 21 target genes by NGS, reporting a concordance for all variants between the primary tumor and metastases of around 72% [80].”
BackgroundFujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., et al. (2017) · Oncology Reports · doi:10.3892/or.2016.5323 · Cited by 74 · cited 2×
“who also underlined the importance of considering the cellularity and degree of necrosis of samples, especially when analyzing lymph nodes [72].”
BackgroundSveen, A., Løes, I. M., Alagaratnam, S., Nilsen, G., Høland, M., Lingjærde, O. C., Sorbye, H., Berg, K. C. G., Horn, A., Angelsen, J.-H., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006225 · Cited by 69
The role of exosomes on colorectal cancer: A review
Ruiz‐López, L., Blancas, I., Garrido, J. M., Mut‐Salud, N., Moya‐Jódar, M., Osuna, A., & Rodríguez‐Serrano, F. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14049 · Cited by 65 · cited 2×
“Moreover, as it has been found that mutant KRAS rather than wt KRAS DNA is loaded preferably into exosomes, the analysis of these vesicles could likely facilitate patient stratification and thus improve clinical management [94].”
BackgroundTórtola, S., Steinert, R., Hantschick, M., Peinado, M. A., Gastinger, I., Stosiek, P., Lippert, H., Schlegel, W., & Reymond, M. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2837 · Cited by 63 · cited 1×
“reported a discordance between KRAS mutations in bone-marrow micro metastases and the primary CRC [78].”
BackgroundHao, Y.-X., Li, Y., Ye, M., Guo, Y.-Y., Li, Q.-W., Peng, X., Wang, Q., Zhang, S., Zhao, H., Zhang, H., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5889 · Cited by 63 · cited 2×
“7% sensitivity and 100% specificity) has been seen for KRAS mutations detected using exosomes from serum [93].”
BackgroundMethodBuim, M. E. C., Fanelli, M. F., Silva, V. S. E., Romero, J. V., Abdallah, E. A., de Mello, C. A. L., Alves, V. S., Ocea, L. M. M., Mingues, N. B., Barbosa, P. N. V. P., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1070991 · Cited by 61 · cited 2×
“analyzed primary tumor tissue and CTCs in 11 patients, observing a concordance of around 64% in KRAS mutational status [87], while other studies obtained a concordance of 71–77% [88,89].”
ResultHanna, N. N., & Cohen, A. M. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.002 · Cited by 58 · cited 1×
“Ovarian metastases occur in 5%–10% of all women with mCRC [62], while brain metastases are relatively rare, with a reported incidence of 1%–2% [63].”
BackgroundSuzuki, Y., Ng, S. B. H., Chua, C., Leow, W. Q., Chng, J., Liu, S., Ramnarayanan, K., Gan, A., Ho, D. L., Ten, R., et al. (2016) · Molecular Oncology · doi:10.1002/1878-0261.12012 · Cited by 56 · cited 3×
“Digital PCR also has a high sensitivity, but is costly and technically difficult to use in these kinds of studies [41].”
BackgroundInfluentialSpindler, K. G., Pallisgaard, N., Appelt, A. L., Andersen, R. F., Schou, J. V., Nielsen, D. L., Pfeiffer, P., Yilmaz, M., Johansen, J. S., Høgdall, E. V. S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.118 · Cited by 51 · cited 1×
“[96] 140 qPCR KRAS 23%/34% NA NA Vidal et al.”
BackgroundTan, I. B., Malik, S., Ramnarayanan, K., McPherson, J. R., Ho, D. L., Suzuki, Y., Ng, S. B., Yan, S., Lim, K. H., Koh, D., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0589-1 · Cited by 50
Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang
Amaro, A. A., Chiara, S., & Pfeffer, U. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9606-4 · Cited by 50 · cited 2×
“This spatial heterogeneity is related to the presence of clones that are genetically distinct as a consequence of evolutionary processes, and also to the co-existence of fully-differentiated cancer cells and immature cancer stem cells within the same cancer [31].”
BackgroundHigh Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer
Jeantet, M., Tougeron, D., Tachon, G., Cortes, U., Archambaut, C., Fromont, G., & Karayan-Tapon, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122015 · Cited by 50
Kovaleva, V., Geißler, A.-L., Lutz, L., Fritsch, R., Makowiec, F., Wiesemann, S. D., Hopt, U. T., Passlick, B., Werner, M., & Laßmann, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0549-8 · Cited by 49 · cited 1×
“Interestingly, the authors revealed that a number of de novo mutations occurred in late disease stages of metachronous CRC lung metastases, several of which may be targetable by specific therapies [73].”
BackgroundKondo, Y., Hayashi, K., Kawakami, K., 三輪, 由., Hayashi, H., & Yamamoto, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3305-6 · Cited by 48
Furuki, H., Yamada, T., Takahashi, G., Iwai, T., Koizumi, M., Shinji, S., Yokoyama, Y., Takeda, K., Taniai, N., & Uchida, E. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.01.224 · Cited by 47 · cited 1×
“Despite the fact that the high concordance between primary tissue and metastasis has led to the approval of guidelines indicating that either type of material can be used indifferently, a proportion of patients for whom there is no concordance between primary and metastatic lesions are destined not to receive optimal…”
BackgroundLi, W., Qiu, T., Guo, L., & Ying, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.014 · Cited by 45 · cited 6×
“, even when samples with low cellularity, which may give rise to false-negative results, were excluded [52].”
BackgroundInfluentialKim, R., Schell, M. J., Teer, J. K., Greenawalt, D. M., Yang, M., & Yeatman, T. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126670 · Cited by 44 · cited 3×
“Similarly, in non-chemo-naive patients, new biopsies of primary or metastatic lesions are probably needed following chemotherapy resistance or insensitivity to fully understand the complexity of the disease and to choose the most appropriate therapy [13].”
BackgroundInfluentialMogensen, M. B., Rossing, M., Østrup, O., Larsen, P. N., Engel, P. J. H., Jørgensen, L. N., Høgdall, E. V. S., Eriksen, J., Ibsen, P. H., Jess, P., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4639-4 · Cited by 43 · cited 2×
“Other studies demonstrated that CNAs differed in primary tumor and metastases, but were rarely observed in CRC-specific genes [23].”
BackgroundUlivi, P., Scarpi, E., Chiadini, E., Marisi, G., Valgiusti, M., Capelli, L., Casadei Gardini, A., Monti, M., Ruscelli, S., Frassineti, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061240 · Cited by 42 · cited 1×
“In particular, higher expression levels of cyclooxygenase-2 (COX2), ephrin type-B receptor 4 (EPHB4), and endothelial nitric oxide synthase (eNOS) were observed in right-sided with respect to left-sided tumors, whereas baseline inflammatory indexes such as neutrophil-to-lymphocyte ratio, platelet-lymphocyte rate, and…”
BackgroundSelf-citationGiardina, T. M., Robinson, C., Grieu‐Iacopetta, F., Millward, M., Iacopetta, B. J., Spagnolo, D. V., & Amanuel, B. (2018) · Pathology · doi:10.1016/j.pathol.2018.01.005 · Cited by 38 · cited 1×
“Recently, NGS targeted panels were proposed for use in clinical practice as they are less expensive and time-consuming [42,43].”
BackgroundChristensen, T. D., Palshof, J. A., Larsen, F. O., Poulsen, T. S., Høgdall, E. V. S., Pfeiffer, P., Jensen, B. V., Yilmaz, M., & Nielsen, D. L. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1433322 · Cited by 34 · cited 1×
“, peritoneum) would seem to be affected by PIK3CA mutations rather than by KRAS status [83,84].”
BackgroundD’Haene, N., Fontanges, Q., Nève, N. D., Blanchard, O., Meléndez, B., Delos, M., Dehou, M., Maris, C., Nagy, N., Rousseau, E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25099 · Cited by 32 · cited 1×
“Recently, NGS targeted panels were proposed for use in clinical practice as they are less expensive and time-consuming [42,43].”
BackgroundGenetic and Epigenetic Intra‐tumour Heterogeneity in Colorectal Cancer
Jones, H. G., Jenkins, G. J. S., Williams, N. W., Griffiths, P., Chambers, P. A., Beynon, J. L., & Harris, D. A. (2017) · World Journal of Surgery · doi:10.1007/s00268-016-3860-z · Cited by 30 · cited 1×
“For this reason, it is recommended that at least two biopsies be taken from different parts of the tumor to take into account ITH and avoid mis-sampling [48].”
BackgroundLi, X., Guo, X., Li, D., Du, X., Yin, C., Chen, C. Y., Wan, F., Bian, Z., Zhang, J., Li, B., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31395 · Cited by 29 · cited 1×
“In fact, different mtDNA mutations were detected in multiple regions of 13 CRCs, in particular in tissue samples from the peripheral part of the tumor [53].”
BackgroundKim, K., Kim, J., Hong, Y. S., Ahn, S., Chun, S., Hong, S., Jang, S. J., Yu, C. S., Kim, J. C., & Kim, T. W. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.490 · Cited by 27
Bonetti, L. R., Barresi, V., Bettelli, S. R., Caprera, C., Manfredini, S., & Maiorana, A. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.12.011 · Cited by 25 · cited 1×
“These authors found that poorly differentiated clusters (PDC), which are the most likely to give rise to metastatic disease, have a different mutational status that overlaps more with nodal metastases than with the tumor, thus demonstrating that peculiar histologic features may indicate ITH [50].”
BackgroundNelson, A., Boone, J., Cartwright, D., Thyagarajan, B., Kincaid, R., Lambert, A. P., Karnuth, K., Henzler, C. M., & Yohe, S. L. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.120 · Cited by 24 · cited 1×
“recommended pooling three tumor sites with adequate cellularity for genetic testing to minimize the risk of false negative results [113].”
BackgroundFarber, L., Efrati, E., Elkin, H., Peerless, Y., Sabo, E., Ben‐Izhak, O., & Hershkovitz, D. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1158-y · Cited by 21
Crobach, S., Ruano, D., van Eijk, R., Schrumpf, M., PALGA group, Fleuren, G. J., van Wezel, T., & Morreau, H. (2016) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.45 · Cited by 20 · cited 1×
“With regard to peritoneal [72], brain [76], and ovarian metastases [77], several authors observed a high concordance rate (>95%) for driver genes between primary tumors and these metastases, whereas Tortola et al.”
BackgroundKleist, B. A., Meurer, T., & Poetsch, M. (2017) · Tumor Biology · doi:10.1177/1010428317692246 · Cited by 20 · cited 1×
“Finally, in an analysis of mitochondrial DNA alterations, a higher discordance was observed between lymph node metastases and primary tumor with respect to distant metastases and primary tumor [81].”
Backgroundde Macêdo, M. P., de Melo, F. M., Ribeiro, H. S. C., Marques, M. C., Kagohara, L. T., Begnami, M. D., Neto, J. C., Ribeiro, J. S., Soares, F. A., Carraro, D. M., et al. (2017) · Europe PMC (PubMed Central) · Cited by 19
Aprile, G., Casagrande, M., Maglio, G. D., Fontanella, C., Rihawi, K., Bonotto, M., Pisa, F. E., Tuniz, F., Pizzolitto, S., & Fasola, G. (2016) · Future Oncology · doi:10.2217/fon-2016-0196 · Cited by 18 · cited 1×
“With regard to peritoneal [72], brain [76], and ovarian metastases [77], several authors observed a high concordance rate (>95%) for driver genes between primary tumors and these metastases, whereas Tortola et al.”
BackgroundctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC
Gazzaniga, P., Raimondi, C., Nicolazzo, C., Gradilone, A., & Cortesi, E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx390.044 · Cited by 17
Büttner, J., Jöhrens, K., Klauschen, F., Hummel, M., Lenze, D., Saeger, W., & Lehmann, A. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.01.007 · Cited by 14 · cited 2×
“The authors suggested that all morphologically different components identified within a tumor must be included in the analysis in order to detect alterations that might be involved in primary drug resistance [49].”
BackgroundIncidence and Prognosis of Synchronous Colorectal Carcinomatosis
Goèré, D., Allard, M., Honoré, C., Dumont, F., & Elias, D. M. (2013) · Future Oncology · doi:10.2217/fon.12.206 · Cited by 10 · cited 1×
“The second most common metastatic site is the lung [58,59], followed by the peritoneum (around 10% of patients) [60,61].”
BackgroundEmergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade
Yamada, T., Takahashi, G., Iwai, T., Takeda, K., Furuki, H., Koizumi, M., Shinji, S., Matsuda, A., Yokoyama, Y., Hotta, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy150.008 · Cited by 1 · cited 2×
“who reported that 17/18 chemo-naive KRAS wt mCRC patients submitted to first-line systemic chemotherapy including EGFR blockade were characterized by the emergence of KRAS mutation [111].”
Background
Cited by
Bhat, A. A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12295 · Cited by 229
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Khaliq, A. M., Erdogan, C., Kurt, Z., Turgut, S. S., Grunvald, M. W., Rand, T., Khare, S., Borgia, J. A., Hayden, D. M., Pappas, S. G., et al. (2022) · Genome Biology · doi:10.1186/s13059-022-02677-z · Cited by 214
“Approximately one third of patients experience disease relapse following curative-intent surgical resection and chemotherapy [2, 3].”
BackgroundPromising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials
Krasteva, N. A., & Georgieva, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061213 · Cited by 161
“CRC most often starts when cells in a polyp begin growing abnormally [49].”
BackgroundLoupakis, F., Sharma, S., Derouazi, M., Murgioni, S., Biason, P., Rizzato, M. D., Rasola, C., Renner, D., Shchegrova, S., Koyen Malashevich, A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00101 · Cited by 130
“Of note, the design of Natera’s mPCR-NGS assay considers clonal heterogeneity, which is a common characteristic of mCRC.(28,29) By contrast, orthogonal ctDNA detection tests such as ddPCR are designed to detect fewer tumor-specific SNVs at a time, providing less coverage for tumor heterogeneity.”
MethodLiao, C., Yu, Y.-L., Lin, Y., Hsu, Y., Chern, Y., Chiang, J., & You, J. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02253-y · Cited by 130
“Because of the heterogeneous nature of CRC, the treatment strategy and outcomes are diverse, even for tumors with the same stage [2].”
Background
Metadata
- Authors
- Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P.
- Affiliations
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
- Corresponding author
- Ulivi, Paola
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-23
- Volume
- 19
- Issue
- 12
- Pages
- 3733
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6321493
- OpenAlex
- W2901481287
- Cited by
- 262
- References
- 116
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 30 · 2023: 25 · 2022: 84 · 2021: 49 · 2020: 20 · 2019: 9
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, tumor heterogeneity, spatial heterogeneity, interpatient variability, metastatic colorectal cancer, anti-EGFR monoclonal antibody, liquid biopsy, minimal residual disease, treatment resistance, personalized medicine, molecular characterization
- MeSH terms
- Liquid Biopsy, Biological Variation, Individual, Humans, Neoplasm Metastasis, Neoplasm Staging, Biomarkers, Tumor, Colorectal Neoplasms, Genetic Heterogeneity, Molecular Diagnostic Techniques, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.